Novel Ibrutinib Combo Shows High Response Rate... - CLL Support
Novel Ibrutinib Combo Shows High Response Rates in MCL, CLL
Written by
whmk
To view profiles and participate in discussions please or .
Read more about...
2 Replies
•
AussieNeilPartnerAdministrator
Thanks! Zilo entry now added to healthunlocked.com/cllsuppo...
Anti-ROR-1 drugs are particularly exciting, as they can selectively target CLL cells over healthy B cells.
Neil
Numerous articles to read here. Some very good over all response rates with Calquence and Loxo 305. Excited to go deep into several of them.
Not what you're looking for?
You may also like...
Response and Survival Rates for FCR and Ibrutinib
Those of you who waded through my post yesterday on clonal evolution will be glad to know this is a...
Ibrutinib pain in cll
My dad who is a 56 yrs old had suffered from ibrutinib pain. It was mainly in knee and legs. As we...
Stopping ibrutinib and imaging in CLL
Hi,
I stopped ibrutinib after almost 8 years. I discuss my thoughts and emotions around saying...
High CLL IN BONE MARROW
I read some where that having a high CLL reading in your bone marrow doesn’t matter, can anyone...
Resistance-Associated Mutations in CLL Patients Treated With Novel Agents
This is slightly complex but good overview of the acquired resistance mechanisms to novel agents....
Related Posts
- Revisiting Richter transformation in the era of novel CLL agents
- Venetoclax Added to Ibrutinib in High-Risk CLL Achieves a High Rate of Undetectable Minimal Residual Disease.
Triplet Regimen Shows Promise in CLL -Zanubrutinib, obinutuzumab, & venetoclax combo achieves rapid undetectable MRD -MedPageToday -07/07/20- Ibrutinib combinations in CLL therapy: scientific rationale and clinical results
ASH 2017: Dr. Richard Furman on the importance of MCL-1 in CLL (chronic lymphocytic leukemia)
